Studies of pathology and VEGF expression in rabbit cerebrospinal fluid metastasis: Application of dynamic contrast-enhanced MRI

Magnetic Resonance Imaging

Volumn 29, Issue 8, 2011, Pages 1101-1109

  Li, Kang an ^a   Zhang, Rui ming ^b   Zhang, Feng ^a   Zhao, Jing long ^a   Li, Yu jie ^a   Wang, Xi fu ^a   Zheng, Lin feng ^a   Hu, Yun sheng ^a   Zhang, Gui xiang ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b Weifang Yi Du Center Hospital   (China)

Author keywords

CSF; DCE MRI; ELISA; Metastasis; VEGF; VX2

Indexed keywords

EOSIN; GADOLINIUM PENTETATE MEGLUMINE; HEMATOXYLIN; VASCULOTROPIN;

ACCURACY; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INFILTRATION; CANCER MODEL; CELL MEMBRANE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID METASTASIS; CISTERNA MAGNA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOPLASM; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PIA MATER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCORING SYSTEM; STAINING; SUBARACHNOID SPACE; TUMOR CELL; TUMOR VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; CEREBROSPINAL FLUID; CONTRAST MEDIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; KINETICS; KNEE; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ORYCTOLAGUS CUNICULUS;

EID: 84860416085     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2011.07.003     Document Type: Article

References (37)

1. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23(5):1011-1027.
2. Hanahan K., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86(3):353-364.
3. Groves M.D. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 2006, 66(10):1609-1610.
4. Cai C., Böttcher M.C., Werner J.A., Mandic R. Differential expression of VEGF121, VEGF165 and VEGF189 in angiomas and squamous cell carcinoma cell lines of the head and neck. Anticancer Res 2010, 30(3):805-810.
5. Margaritescu C., Pirici D., Stînga A., Simionescu C., Raica M., Mogoanta L., et al. VEGF expression and angiogenesis in oral squamous cell carcinoma: an immunohistochemical and morphometric study. Clin Exp Med 2010, 10(4):209-214.
6. Goerner M., Seiwert T.Y., Sudhoff H. Molecular targeted therapies in head and neck cancer - an update of recent developments. Head Neck Oncol 2010, 14:2-8.
7. Brinegar C., Schmitter S.S., Mistry N.N., Johnson G.A., Liang Z.P. Improving temporal resolution of pulmonary perfusion imaging in rats using the partially separable functions model. Magn Reson Med 2010, 64(4):1162-1170.
8. Di Giovanni P., Azlan C.A., Ahearn T.S., Semple S.I., Gilbert F.J., Redpath T.W. The accuracy of pharmacokinetic parameter measurement in DCE-MRI of the breast at 3T. Phys Med Biol 2010, 55(1):121-132.
9. El Khouli R.H., Macura K.J., Barker P.B., Habba M.R., Jacobs M.A., Bluemke D.A. Relationship of temporal resolution to diagnostic performance for dynamic contrast enhanced MRI of the breast. J Magn Reson Imaging 2009, 30(5):999-1004.
10. Knopp M.V., Giesel F.L., Marcos H., von Tengg-Kobligk H., Choyke P. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging 2001, 12(4):301-308.
11. Tofts P., et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, (10):223-232.
12. Thukral A., et al. Inflammatory breast cancer: dynamic contrast-enhanced MRI in patients receiving bevacizumab - initial experience. Radiology 2007, 244:727-735.
13. Knopp M.V., Weiss E., Sinn H.P., Mattern J., Junkermann H., Radeleff J., et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging 1999, 10(3):260-266.
14. Hawighorst H., Knapstein P.G., Weikel W., Knopp M.V., Zuna I., Knof A., et al. Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 1997, 57(21):4777-4788.
15. Barrett T., Brechbiel M., Bernardo M., Choyke P.L. MRI of tumor angiogenesis. J Magn Reson Imaging 2007, 26(2):235-249.
16. Jordan B.F., Runquist M., Raghunand N., Baker A., Williams R., Kirkpatrick L., et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. Neoplasia 2005, 7(5):475-485.
17. Cheng H.L., Wallis C., Shou Z., Farhat W.A. Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights. J Magn Reson Imaging 2007, 25(1):137-145.
18. Provenzale J.M. Imaging of angiogenesis: clinical techniques and novel imaging methods. Am J Roentgenol 2007, 188(1):11-23.
19. Ren J., Huan Y., Wang H., Chang Y.J., Zhao H.T., Ge Y.L., et al. Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. Clin Radiol 2008, 63(2):153-159.
20. Cooper R.A., Carrington B.M., Loncaster J.A., et al. Tumor oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. Radiother Oncol 2000, 57(1):53-59.
21. McMahon C.J., Bloch B.N., Lenkinski R.E., Rofsky N.M. Dynamic contrast-enhanced MR imaging in the evaluation of patients with prostate cancer. Magn Reson Imaging Clin N Am 2009, 17(2):363-383.
22. Collins D.J., Padhani A.R. Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Eng Med Biol Mag 2004, 23(5):65-83.
23. Bian J., Sha L., Yang C., Sun C.S. Three-dimensional dynamic contrast-enhanced MR angiography for evaluating recipient vessels in orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int 2008, 7(5):476-480.
24. Chen J., Yao J., Thomasson D. Automatic determination of arterial input function for dynamic contrast enhanced MRI in tumor assessment. Med Image Comput Comput Assist Interv 2008, 11:594-601.
25. Yankeelov T.E., Luci J.J., Lepage M., Li R., Debusk L., Lin P.C., et al. Quantitative pharmacokinetic analysis of DCE-MRI data without an arterial input function: a reference region model. Magn Reson Imaging 2005, 23(4):519-529.
26. Sampath P., Weaver C.E., Sungarian A., Cortez S., Alderson L., Stopa E.G. Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma. Cancer Control 2004, 11(3):174-180.
27. Friedrichs K., Gluba S., Eidtmann H., Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993, 72:3641-3647.
28. McDonnell C.O., Hill A.D.K., Mcnamara D.A., Walsh T.N., Bouchier-Hayes D.J. Tumour micrometastases: the influence of angiogenesis. Eur J Surg Oncol 2000, 26(2):105-115.
29. Cristofanilli M., Charnsangavej C.H., Hortobagyyi G.N. Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev 2002, 1(6):415-426.
30. Costa C., Soares R., Schmitt F. Angiogenesis: now and then. APMIS 2004, 112(8):402-412.
31. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9(6):669-676.
32. Heisen M., Fan X., Buurman J., van Riel N.A., Karczmar G.S., ter Haar Romeny B.M. The influence of temporal resolution in determining pharmacokinetic parameters from DCE-MRI data. Magn Reson Med 2010, 63(3):811-816.
33. Wang H., Miao Y., Zhou K., Yu Y., Bao S., He Q., et al. Feasibility of high temporal resolution breast DCE-MRI using compressed sensing theory. Med Phys 2010, 37(9):4971-4981.
34. Dafni H., Kim S.J., Bankson J.A., Sankaranarayanapillai M., Ronen S.M. Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation. Magn Reson Med 2008, 60(4):822-833.
35. Drevs J., Hofmann I., Hugenschmidt H., Wittig C., Madjar H., Muller M., et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000, 60(17):4819-4824.
36. Brekken R.A., Overholser J.P., Stastny V.A., Waltenberger J., Minna J.D., Thorpe P.E. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000, 60(18):5117-5124.
37. Gu Z.P., Wang Y.J., Li J.G., Zhou Y.A. VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma. World J Gastroenterol 2002, 8(1):44-48.